Patents Represented by Attorney Gabriel Lopez
  • Patent number: 6348337
    Abstract: A process useful for the preparation of intermediates in synthesis or semi-synthesis of paclitaxel analogs wherein a starting taxane such as 10-deacetylbaccatin III is deacetylated at the C-4 position using a microorganism or an enzyme derived therefrom to provide 4-deacetyltaxanes, such as 4,10-dideacetylbaccatin III.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: February 19, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald L. Hanson, Ramesh N. Patel
  • Patent number: 6331316
    Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sizes and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: December 18, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ismat Ullah, Gary J. Wiley
  • Patent number: 6310201
    Abstract: Novel &bgr;-lactams finding utility as intermediates in the preparation of sidechain-bearing taxes such as tall and tall derivatives. The present invention also relates to novel methods of coupling &bgr;-lactams to form such sidechain-bearing taxes, and to novel sidechain-bearing taxes.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: October 30, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: John K. Thottathil, Ivan D. Trifunovich, David J. Kucera, Wen-Sen Li
  • Patent number: 6307071
    Abstract: Process for synthesizing paclitaxel by treating baccatin III with a strong base in a solvent, adding an electrophile to the solution to form a 7-O-protected baccatin III derivative, reacting the 7-O-protected baccatin III derivative with a protected paclitaxel sidechain in a solvent such that the protected paclitaxel sidechain is coupled to the 13-hydroxyl of the 7-O-protected baccatin III, and subsequently deprotecting the protected paclitaxel sidechain and the 7-O protecting group to form paclitaxel, and intermediates used therein.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: October 23, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis S. Gibson
  • Patent number: 6262127
    Abstract: This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF&agr;, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: July 17, 2001
    Assignee: Novartis AG
    Inventors: Murat Acemoglu, Siegfried Bantle, David Bodmer, Salvatore Cammisuli, Peter Hiestand, Fritz Nimmerfall, Georg Stoll
  • Patent number: 6255100
    Abstract: It has been found that nonimmunosuppressive, cyclophilin-binding cyclosporins are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such cyclosporins include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: July 3, 2001
    Assignee: Novartis AG
    Inventors: Soo Young Ko, Hans Kobel, Brigitte Besemer-Rosenwirth, Dieter Seebach, RenéP. Traber, Roland Wenger, Pietro Bollinger
  • Patent number: 6248908
    Abstract: A process for the synthesis of a C-4 methyl carbonate paclitaxel analog from 10-deacetylbaccatin III by the selective reduction of the acetate at the C-4 position of 10-deacetylbaccatin using Red-Al.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: June 19, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventor: Joydeep Kant
  • Patent number: 6242614
    Abstract: A process for the synthesis of paclitaxel from 10-deacetylbaccatin-III which is protected at the 7-position with a dialkylalkoxysilyl protecting group having the formula —Si(R)2(OR′).
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: June 5, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Purushotham Vemishetti, Francis S. Gibson, John L. Dillon
  • Patent number: 6239124
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: May 29, 2001
    Assignee: Novartis AG
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Patent number: 6224910
    Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: May 1, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ismat Ullah, Gary J. Wiley
  • Patent number: 6215000
    Abstract: Disclosed are crystalline complexes of baccatin III with imidazole, 2-methylimidazole or isopropanol, which are useful for isolating baccatin III from plant tissue cell culture and plant extracts containing baccatin Ill.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: April 10, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis S. Gibson, Jianmei Wei, John L. Dillon, Jr., Purushotham Vemishetti
  • Patent number: 6207831
    Abstract: The invention relates to new fluorescent dyes of formula (I) which can be used in high throughput screening both, on the solid phase as well as in homogeneous solution.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: March 27, 2001
    Assignee: Novartis AG
    Inventors: Manfred Auer, Hubert Gstach
  • Patent number: 6204244
    Abstract: The present invention provides for the use glycine in the preparation of a medicament or nutritional formulation for the prophylaxis and/or therapy of renal dysfunction induced by cyclosporins or ascomycins.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: March 20, 2001
    Assignee: Novartis Nutrition AG
    Inventor: Heinz Schneider
  • Patent number: 6200985
    Abstract: Rapamycin derivatives are disclosed of the formula: wherein the variables are in the specification.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: March 13, 2001
    Assignee: Novartis AG
    Inventors: Sylvain Cottens, Richard Sedrani
  • Patent number: 6165746
    Abstract: A process for the recombinant preparation in a bacterial host of the mature form of a mammalian protein or peptide of formula X-Pro-Z, which is subject to processing by endogenous bacterial aminopeptidases is provided. In the formula X-Pro-Z, X is a single N-terminal amino acid other than proline, and Z is the remaining sequence of amino acid residues of the protein or peptide. The process comprises inserting into a cell of the bacterial host an appropriate vector containing DNA coding for Met-Y-X-Pro-Z, in which Y is a natural amino acid that is specifically cleavable in vitro from X-Pro-Z by an aminopeptidases and that imparts resistance to in vivo processing by endogenous bacterial aminopeptidases. The cell is then induced to express the expression product Met-Y-X-Pro-Z which is then treated with an appropriate aminopeptidase to cleave off Met and Y.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 26, 2000
    Assignee: Novartis AG
    Inventors: Markus Heitzmann, Rao Movva, Paul Ramage
  • Patent number: 6162622
    Abstract: An enzymatic hydroxylation method for the preparation of compounds useful as intermediates in the preparation of taxanes such as 6-.alpha.-hydroxy-7-deoxypaclitaxel, wherein one or more C-6 hydrogen-bearing taxanes are contacted with an enzyme or microorganism capable of hydroxylating said C-6 carbon to give C-6 hydroxyl-bearing taxane.
    Type: Grant
    Filed: January 14, 1999
    Date of Patent: December 19, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald L. Hanson, Ramesh N. Patel
  • Patent number: 6121314
    Abstract: Non-greasy topical solutions, emulsion gels or lotions comprising as the active agent a compound of formula I ##STR1## and a lower alkanol, and if desired together with a solubilizing agent or an oil phase such as isopropyl myristate are useful delivery systems.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: September 19, 2000
    Assignee: Novartis AG
    Inventors: Friedrich Richter, Michel Steiger
  • Patent number: 6117892
    Abstract: Plant-protecting mixtures of active ingredients having a synergistically increased action, wherein component I is a compound having a plant-immunizing action of the formula I ##STR1## in which Z is CN, COOH or a salt thereof, CO--OC.sub.1 -C.sub.4 alkyl or CO--SC.sub.1 -C.sub.4 alkyl;and wherein component II is a compound selected from the group consisting of propiconazole, difenoconazole, penconazole, fenpropimorph, fenpropidine, cyprodinil, metalaxyl, R-metalaxyl and pyroquilon.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: September 12, 2000
    Assignee: Novartis Finance Corp.
    Inventors: Wilhelm Ruess, Gertrude Knauf-Beiter, Ruth Beatrice Kung, Helmut Kessmann
  • Patent number: 6096785
    Abstract: A method for the use of at least one amino acid selected from the group consisting of glycine, alanine and serine, or the physiologically acceptable salts thereof (component (a)), in the preparation of a medicament or nutritional formulation for the prophylaxis and/or therapy of renal dysfunction induced by cyclosporins or ascomycins.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: August 1, 2000
    Assignee: Novartis Nutrition AG
    Inventor: Heinz Schneider
  • Patent number: 6087388
    Abstract: When used in admixture with mancozeb, chlorothalonil, a copper salt, folpet, fluazinam or cymoxanil (it being possible for the latter to be used also together with one of the other five components), metalaxyl having a high R-enantiomer content of more than 70% by weight, or pure R-metalaxyl, exhibits a markedly increased fungicidal action against plant diseases as compared with a similar mixture in which metalaxyl is used in the form of the racemate.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: July 11, 2000
    Assignee: Novartis Corp.
    Inventors: Cosima Nuninger, John Edward Nicholas Goggin, Dino Sozzi